Credit Ihub mb. I sent it on to the EPA Drug Initiative, the contact person for which emailed me this morning saying he had sent it on to their people. Hopefully, they will get it into the right hands promptly.
Eur J Prev Cardiol. 2013 Dec 16. [Epub ahead of print]
The association between dietary omega-3 fatty acids and cardiovascular death: the Singapore Chinese Health Study.
Koh AS, Pan A, Wang R, Odegaard AO, Pereira MA, Yuan JM, Koh WP.
Although studies suggest that omega-3 fatty acids intake may reduce cardiovascular disease (CVD) mortality risk, few studies have differentiated dietary eicosapentaenoic/docosahexaenoic acid (EPA/DHA) from alpha-linolenic acid (ALA), and epidemiological research in Asian populations is limited.
The Singapore Chinese Health Study is a population-based cohort that recruited 63,257 Chinese adults aged 45-74 years from 1993 to 1998. Usual diet was measured at recruitment using a validated semiquantitative food-frequency questionnaire, and mortality information was identified via registry linkage up to 31 December 2011. Cox proportional hazard models were used to calculate hazard ratios (HRs) with adjustment for potential confounders.
We documented 4780 cardiovascular deaths (including 2697 coronary heart disease (CHD) deaths and 1298 stroke deaths) during 890,473 person-years of follow up. Omega-3 fatty acids intake was monotonically associated with reduced risk of cardiovascular mortality. Compared to the lowest quartile, the HR was 0.88 (95% confidence interval, CI, 0.81-0.96), 0.88 (95% CI 0.80-0.97), and 0.83 (95% CI 0.74-0.92) for the second, third, and highest quartile, respectively (p-trend?=?0.003). Both EPA/DHA and ALA were independently associated with reduced risk of cardiovascular mortality: HR comparing extreme quartiles was 0.86 (95% CI 0.77-0.96, p-trend?=?0.002) and 0.81 (95% CI 0.73-0.90, p-trend?
United Healthcare (using Express Scripts as its PBM) does cover Vascepa as Tier 2, at least for the plan I am on. Spoke with rep, who said per my plan, cost is $50 for a 90 day supply. They said it can be Tier 2 or 3, but on my plan it is priced as if it were Tier 2, as above.
And there are a lot of reasons (e.g., JELIS) to believe that REDUCE IT data will show CVD event reduction in the Vascepa treatment arm.
In the meantime, cardiologists and PCPs, as they become educated, will continue prescribing Vascepa in increasing numbers. AMRN is a very underappreciated stock given the likely commercial success of Vascepa.